跳至主要内容
临床试验/ISRCTN58396079
ISRCTN58396079已完成不适用

A randomised controlled trial for the optimization of the viability of stem cells derived from umbilical CORd blood after maternal supplementation with DHA during the second or third trimester of pregnancy

SmartBank (Italy)0 个研究点目标入组 150 人开始时间: 2013年10月8日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. Age >18 years
  • 2. Absence of: diabetes, hypertension or any other type of pathology requiring pharmacological therapy, genetic diseases, chromosome abnormalities and/or congenital malformations in the foetus and the absence of infectious disease (hepatitis B, hepatitis C, HIV and cytomegalovirus).

排除标准

  • 1. Age <18 years
  • 2. Presence of: diabetes, hypertension or any other type of pathology requiring pharmacological therapy, genetic diseases, chromosome abnormalities and/or congenital malformations in the foetus and the presence of infectious disease (hepatitis B, hepatitis C, HIV and cytomegalovirus).
  • 3. Cord blood samples with a volume of less than 80 ml and/or less than 70% cell vitality are excluded from the study.

研究者

发起方
SmartBank (Italy)

相似试验

CORDHA study: Optimization of the viability of stem... | 临床试验